MedTrace Logo

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

NCT00282581 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2014-01-22

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with HIV infection

Conditions

Interventions

BIOLOGICAL

MVA Smallpox Vaccine

0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Margaret Fischl, MD · University of Miami AIDS clinical research unit

  • Rafael E Campo, MD · University of Miami

  • Cecilia Shikuma, MD · University of Hawaii- Honolulu

  • Daniel Pearce, DO · AltaMed Health Services, Los Angeles

  • Jacob Lalezari, MD · Quest Clinical Research, San Francisco

  • Scott D Parker, MD · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282581 on ClinicalTrials.gov